Skip to main content
Top
Published in: Translational Behavioral Medicine 4/2011

01-12-2011

News from the CDC: Translating science into HCV infection screening recommendations

Authors: Rebecca L Morgan, MPH, Bryce D Smith, PhD, Geoff A Beckett, PA-C, MPH

Published in: Translational Behavioral Medicine | Issue 4/2011

Login to get access

Excerpt

Hepatitis C virus (HCV) infects an estimated 3.2 million persons in the U.S. [1]. Recent estimates indicate that in 2007, the mortality rate of HCV was 4.6 deaths per 100,000 population (n=15,106) [2]. Chronic HCV is a leading cause of hepatocellular carcinoma and its complications are a leading indication for liver transplantation [3, 4]. In addition, an estimated 39% to 85% of infected persons are unaware of their status [5, 6]. …
Literature
1.
go back to reference Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.PubMed Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.PubMed
3.
go back to reference Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335-1374.PubMedCrossRef Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335-1374.PubMedCrossRef
4.
go back to reference Velázquez RF, Rodríguez M, Navascués CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37(3):520-527.PubMedCrossRef Velázquez RF, Rodríguez M, Navascués CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37(3):520-527.PubMedCrossRef
5.
go back to reference Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50(6):1750-1755.PubMedCrossRef Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50(6):1750-1755.PubMedCrossRef
6.
go back to reference Roblin DW, Smith BD, Weinbaum CM, Sabin ME. Hepatitis C virus screening practices and prevalence in an MCO, 2000–2007. Am J Manag Care. 2011;17(8):548-555.PubMed Roblin DW, Smith BD, Weinbaum CM, Sabin ME. Hepatitis C virus screening practices and prevalence in an MCO, 2000–2007. Am J Manag Care. 2011;17(8):548-555.PubMed
7.
go back to reference IOM (Institute of Medicine). Hepatitis and liver cancer: A national strategy for prevention and control of hepatitis B and C. Washington, DC: The National Academies Press; 2010. IOM (Institute of Medicine). Hepatitis and liver cancer: A national strategy for prevention and control of hepatitis B and C. Washington, DC: The National Academies Press; 2010.
9.
go back to reference Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1-39. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1-39.
Metadata
Title
News from the CDC: Translating science into HCV infection screening recommendations
Authors
Rebecca L Morgan, MPH
Bryce D Smith, PhD
Geoff A Beckett, PA-C, MPH
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Translational Behavioral Medicine / Issue 4/2011
Print ISSN: 1869-6716
Electronic ISSN: 1613-9860
DOI
https://doi.org/10.1007/s13142-011-0089-0

Other articles of this Issue 4/2011

Translational Behavioral Medicine 4/2011 Go to the issue